CAR-T therapy for relapsed or refractory IgG4-related disease
Part of Immune system & allergy clinical trials.
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with IgG4-related disease according to the 2019 criteria.
- Your disease affects at least two important organs or systems (like the pancreas, bile ducts, kidneys, or brain lining).
- Your disease is still active after 3 months of steroids or rituximab, or it came back within 6 months after finishing treatment.
- Your major organs (bone marrow, liver, kidneys, heart, blood clotting) are working well enough based on standard tests.
- If you could become pregnant, you must use effective birth control during the study and for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using immune cells (CAR-NK) designed to target and kill specific cells that may cause IgG4-related disease (IgG4-RD). It is for people whose IgG4-RD has come back or not responded to standard treatments.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat inflammatory bowel disease (IBD) that has not responded to standard treatments. The therapy is engineered to target specific immune cells involved in IBD inflammation.
Hear when a new IgG4-Related Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.